MTD:NYSEMettler-Toledo International, Inc. Analysis
Data as of 2026-03-10 - not real-time
$1,236.30
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Mettler‑Toledo delivered a strong Q4 finish, posting EPS of $13.36 versus the consensus $12.76 and an 8% revenue increase to $1.1 billion, underscoring its resilient demand across laboratory and industrial segments. Operating margins remain robust at 30.7% and free cash flow exceeds $687 million, supporting continued investment in automation and AI‑driven solutions. The company’s balance sheet shows ample liquidity with $66.9 million cash, though debt sits near $2.27 billion, resulting in a neutral debt‑to‑equity profile. Technical indicators signal mixed short‑term sentiment: the 14‑day RSI is low at 29, suggesting oversold conditions, while the MACD remains bearish and the price trades below its 20‑day (1339) and 50‑day (1392) SMAs. Support at $1,193 holds the current price of $1,236, but the 30‑day volatility of 24% and a beta of 1.44 point to heightened price swings. Valuation appears stretched, with a market price of $1,236 versus a DCF‑derived fair value of roughly $550 and a forward P/E of 24 against the industry average of 25.3. The market sentiment index reads “Extreme Greed” at 80.6, hinting at potential overenthusiasm. Overall, the stock combines solid earnings momentum with a premium valuation and elevated risk factors.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Oversold RSI indicating near‑term price rebound potential
- Recent earnings beat and accelerating revenue growth
- Increasing trading volume supporting momentum
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strong operating margins and free cash flow generation
- Valuation premium relative to DCF and peers
- Broad product diversification across life‑science and industrial markets
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- Significant overvaluation risk if market corrects toward DCF
- High regulatory exposure in the diagnostics segment
- Absence of dividend reduces total return appeal
Key Metrics & Analysis
Financial Health
Revenue Growth8.10%
Profit Margin21.59%
P/E Ratio29.4
ROA20.35%
P/B Ratio-1064.9
Op. Cash Flow$955.8M
Free Cash Flow$687.1M
Industry P/E25.4
Technical Analysis
TrendNeutral
RSI29.4
Support$1,192.85
Resistance$1,422.36
MA 20$1,338.78
MA 50$1,392.00
MA 200$1,319.65
MACDBearish
VolumeIncreasing
Fear & Greed Index80.57
Valuation
Fair Value$549.71
Target Price$1,501.38
Upside/Downside21.44%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.19
Volatility23.92%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.